Investment Rating - The report assigns an "Outperform" rating to the company, indicating an expected total return over the next 12-18 months that will exceed the return of its relevant broad market benchmark [18][33][34]. Core Insights - The company's performance stabilized and rebounded in Q1 2024, with a revenue of RMB 1.94 billion, up 31.78% YoY, while the net profit attributable to shareholders was a loss of RMB 34 million, improving by 79.62% YoY [5][18]. - The main business decline in 2023 was attributed to reduced customer budgets and delayed order acceptance, with total revenue for 2023 at RMB 1.984 billion, down 12.98% YoY [5][18]. - The company is focusing on deepening its cornerstone business while expanding into new sectors, particularly in big data intelligence and electronic forensics, maintaining its market leadership [8][18]. - Strategic investments are being made in new cyberspace security and digital government sectors, with the establishment of a wholly-owned subsidiary to accelerate enterprise digitalization [8][18]. Financial Summary - Revenue and profit forecasts indicate a recovery, with expected revenues of RMB 2.52 billion in 2024, RMB 3.03 billion in 2025, and RMB 3.56 billion in 2026, reflecting growth rates of 27%, 20%, and 17.7% respectively [6][27]. - The gross profit margin is projected to gradually increase, with estimates of 46.0% in 2024, 46.2% in 2025, and 46.3% in 2026 [6][27]. - The company reported a net profit attributable to shareholders of RMB 277 million in 2024, RMB 340 million in 2025, and RMB 416 million in 2026, indicating a significant turnaround from a loss of RMB 206 million in 2023 [6][27]. Business Strategy - The company is implementing the "8848+" strategy, aiming to consolidate and expand its four major industries by 2025, while also focusing on innovation and digital transformation [24][25]. - The recent rebranding to "Guotou Intelligent (Xiamen) Information Co., Ltd." is intended to enhance strategic leadership and resource allocation [23][24]. - The company is also addressing new market demands in drone safety products, focusing on improving identification and tracking technologies [9][18].

Investment Rating - The report assigns an "Outperform" rating to the company, with a target price of 46.20 yuan, reflecting a 12x P/E ratio for 2024 [7]. Core Insights - The company is experiencing a seasonal increase in accounts receivable and inventory, with accounts receivable rising by 11% to 30.03 billion yuan in Q1 2024, while inventory increased by 40% to 12.61 billion yuan [3][12]. - The company has a strong grassroots sales channel, with 3,990 sales personnel as of the end of 2023, significantly surpassing industry peers [4][19]. - The HPV vaccine is entering a mature phase, with a current vaccination rate of 21% among eligible women, indicating potential for growth [4][21]. - The company has secured exclusive distribution rights for GSK's shingles vaccine, with minimum procurement amounts projected at 3.44 billion yuan for 2024 [4][18]. - The company is expanding its product pipeline, including vaccines for tuberculosis, pneumonia, influenza, and rabies, and plans to acquire Chen'an Biotech to enter the diabetes and obesity treatment market [4][31]. Summary by Sections Accounts Receivable and Inventory Increase in Q1 2024 - Accounts receivable increased by 11% to 30.03 billion yuan, while inventory rose by 40% to 12.61 billion yuan [12][16]. - The increase in accounts receivable is attributed to seasonal factors, with a notable decrease in turnover days compared to peers [3][12]. Company's Operational Advantages and "Second Curve" - The company has a robust grassroots channel and a dual-driven model of technology and market, with R&D spending of 1.35 billion yuan in 2023 [4][19]. - The company is entering a "second curve" by diversifying its product offerings and expanding into new therapeutic areas [20][28]. - The shingles vaccine market has a potential capacity of 164.8 billion to 1,648.5 billion yuan, depending on penetration rates [26][27]. Shareholder Return Attributes - The company plans to distribute a total dividend of at least 10 yuan per 10 shares, corresponding to a dividend yield of 3.5% [5][32]. - A share buyback of 300 million yuan has been completed, reflecting the company's commitment to returning value to shareholders [5][32]. Profit Forecast and Valuation - The company is projected to achieve net profits of 9.22 billion, 11.32 billion, and 12.71 billion yuan for 2024-2026, with respective growth rates of 14%, 23%, and 12% [7][34]. - The revenue forecast for 2024 is 58.85 billion yuan, with a year-on-year growth of 11.2% [35].

Investment Rating - The report assigns an "OUTPERFORM" rating to the company with a target price of Rmb 46.2 [1]. Core Insights - The report explores the operational turning point of the company, highlighting its strong grassroots channels, significant R&D investments, and potential growth areas in the HPV and shingles vaccine markets [2][4][8]. Summary by Sections 1. Accounts Receivable and Inventory Increase in Q1 2024 - The company's accounts receivable increased by 11% to Rmb 30.03 billion, while inventory rose by 40% to Rmb 12.61 billion, attributed to seasonal factors [3][14]. - The accounts receivable turnover days are significantly lower than peers at 162 days, indicating a low risk of uncollectible accounts [3][16]. 2. Operational Advantages and "Second Curve" - The company boasts a robust grassroots channel with 3,990 sales personnel, far exceeding industry peers, and has secured agency rights for major products from GSK and Merck [4][21]. - Revenue in Q1 2024 grew by 2% year-on-year, indicating the HPV vaccine may be entering a mature phase, with a current vaccination rate of 21% among eligible women [4][24]. - The company is set to officially launch GSK's shingles vaccine in 2024, with projected minimum procurement amounts of Rmb 34.4 billion, Rmb 68.8 billion, and Rmb 103.2 billion for 2024-2026 [4][20]. - The company has a rich pipeline of self-developed products in various stages, including tuberculosis and influenza vaccines, and plans to acquire a company to expand into diabetes and weight loss medications [4][31][34]. 3. Shareholder Return Attributes - The company plans to distribute a total dividend of at least Rmb 10 per 10 shares for 2023 and 2024, corresponding to a dividend yield of 3.5% [5][35]. - A share buyback of Rmb 300 million has been completed, and an employee stock ownership plan has been implemented, with 2,910,000 shares purchased [5][36]. 4. Earnings Forecast and Valuation - The company’s projected net profits for 2024-2026 are Rmb 9.22 billion, Rmb 11.32 billion, and Rmb 12.71 billion, reflecting year-on-year growth rates of 14%, 23%, and 12% respectively [8][37]. - The report assigns a P/E ratio of 12x for 2024, leading to a target price of Rmb 46.20, with a market capitalization estimate of Rmb 922 billion to Rmb 1,106 billion [8][39].

63 Notice to Japanese investors: This research report is distributed by Haitong International Securities Company Limited and intended to be distributed to Financial Services Providers or Registered Financial Institutions engaged in investment management (as defined in the Japan Financial Instruments and Exchange Act ("FIEL") Art. 61(1), Order for Enforcement of FIEL Art. 17-11(1), and related articles). Notice to Indian investors: The research report is distributed by Haitong Securities India Private Limite ...

4. 风险提示 Equity – Asia Research 本研究报告由海通国际分销，海通国际是由海通国际研究有限公司，海通证券印度私人有限公司，海通国际株式会社和海通国际证券集团其他各成员单位的证券 研究团队所组成的全球品牌，海通国际证券集团各成员分别在其许可的司法管辖区内从事证券活动。关于海通国际的分析师证明，重要披露声明和免责声明，请 参阅附录。(Please see appendix for English translation of the disclaimer) 1. 易普力：综合性大型民爆企业 2. 受益于民爆行业整合 3. 募投项目及盈利预测 For full disclosure of risks, valuation methodologies and target price formation on all HTI rated stocks, please refer to the latest full report on our website at equities.htisec.com 2 公司为综合性大型民爆企业 资料来源：公司官网，公司23年年报，海通国际整理 3 国务 ...

Group 1 - The core viewpoint of the report indicates that the recent rise in Hong Kong stocks is primarily driven by domestic real estate policy initiatives and increased expectations for interest rate cuts by the Federal Reserve [1][31]. - Following April 20, Hong Kong stocks resumed an upward trend due to the implementation of various real estate policies aimed at reducing inventory, including the "430 Politburo meeting" directive to "digest existing properties" and the "517 real estate new policy" [1][31]. - The report notes that while the production side of the real estate sector is recovering quickly, the sales side is improving slowly, suggesting that the current market rally is more about sentiment than actual improvements in sales and investment data [1][31]. Group 2 - In June, the Hong Kong stock market experienced a significant decline, attributed to market consolidation and the slow effectiveness of previous policies, with the domestic economic fundamentals remaining weak [7][22]. - The report highlights that the Hang Seng Index fell from 19,636 points to 17,719 points between May 20 and June 28, marking a cumulative decline of 13.6% [31]. - The report anticipates that the second half of the year will see positive changes in the fundamentals, capital flows, and market sentiment, which could support further upward movement in Hong Kong stocks [23]. Group 3 - The report emphasizes that the overall net profit growth for Hong Kong stocks in 2023 is expected to turn positive at 2.6%, improving from a negative 4.8% in the first half of 2023, indicating a gradual recovery in corporate earnings [13]. - It is projected that the actual GDP growth rate in China for 2024 could reach around 5% to 5.5%, supported by ongoing policy implementations and a recovery in the inventory cycle [13]. - The report also notes that flexible foreign capital has been a significant contributor to the inflow of foreign investment in Hong Kong stocks, with approximately 62 billion yuan net inflow from flexible foreign capital from the Spring Festival to the end of May [13].

Morning Meeting Summary 电网投资景气度持续/工业气体月度跟踪/关注设备更新贷款财政贴息政策 08 Jul 2024 | | | Last 1D (%) | |----------------------|---------------|---------------| | MSCI China | 57.8 | -0.99 | | Hang Seng | 17,800 | -1.27 | | Shanghai Comp Topix | 2,950 2,884 | -0.26 -0.49 | | Nikkei 225 | 40,912 | 0.00 | | Kospi | 2,862 | 1.32 | | BSE Sensex | 79,997 | -0.07 | | MSCI India | 1,091.4 | 0.49 | | Taiwan Taiex | 23,557 | 0.14 | | S&P/ASX 200 | 7,822 | -0.12 | | Dow Jones | 39,376 | 0.17 | | S&P 500 | 5,567 | 0.54 | | Nasdaq C ...

行业研究/传媒 证券研究报告 行业月报 7 月报:中报季业绩月关注优质白马, 2024 世界人工智能大会即将举行 投资要点: 月报观点:24 年中报季即将来临,我们建议,积极关注板块中业绩优、高股息 等方向优质标的。1)港股互联网:【腾讯控股、快手-W、哔哩哔哩-W、心动公 司】。2)营销板块:【分众传媒、易点天下】。3)游戏板块:【恺英网络、神州 泰岳、世纪华通】等。4)影视内容:关注暑期档【光线传媒、万达电影、博纳 影业、上海电影】等; 5)出版板块:积极转型【南方传媒、皖新传媒、城市 传媒、时代出版】;高分红【中文传媒、凤凰传媒、中南传媒】。 2024 世界人工智能大会将于 7 月 4 日在上海举行。本次大会主题为"以共商促共 享,以善治促善智",打造"会议论坛、展览展示、评奖赛事、智能体验"四大板 块,论坛时间为 7 月 4 日至 6 日,展览时间为 7 月 4 日至 7 日。我们长期看好 AI 应用方向发展,标的建议关注:【昆仑万维、焦点科技、盛天网络】等。 港股互联网。上周(2024.06.21-2024.06.28)主要港股互联网公司涨幅前三汇通 达网络(3.81%)、网易-S(3.54%)、友 ...

行业研究/传媒 证券研究报告 行业月报 7 月报:中报季业绩月关注优质白马, 2024 世界人工智能大会即将举行 投资要点: 月报观点:24 年中报季即将来临,我们建议,积极关注板块中业绩优、高股息 等方向优质标的。1)港股互联网:【腾讯控股、快手-W、哔哩哔哩-W、心动公 司】。2)营销板块:【分众传媒、易点天下】。3)游戏板块:【恺英网络、神州 泰岳、世纪华通】等。4)影视内容:关注暑期档【光线传媒、万达电影、博纳 影业、上海电影】等; 5)出版板块:积极转型【南方传媒、皖新传媒、城市 传媒、时代出版】;高分红【中文传媒、凤凰传媒、中南传媒】。 2024 世界人工智能大会将于 7 月 4 日在上海举行。本次大会主题为"以共商促共 享,以善治促善智",打造"会议论坛、展览展示、评奖赛事、智能体验"四大板 块,论坛时间为 7 月 4 日至 6 日,展览时间为 7 月 4 日至 7 日。我们长期看好 AI 应用方向发展,标的建议关注:【昆仑万维、焦点科技、盛天网络】等。 港股互联网。上周(2024.06.21-2024.06.28)主要港股互联网公司涨幅前三汇通 达网络(3.81%)、网易-S(3.54%)、友 ...

行业研究/旅游服务业 证券研究报告 行业周报 社服板块 2024 年中报前瞻 投资要点: 【核心观点】 1. 社服板块中报前瞻:出行价格中枢有所回落,高基数下业绩或承压 (1)免税:中国中免:据海口海关统计,2024 年 4 月及 5 月,海南离岛免税合计 销售额 41.46亿元,去年同期为 71.13 亿元,同比下滑 41.71%;预计 2Q24 收入 130-145 亿元,利润 12.8-14 亿元。 (2)酒店:首旅酒店:24 年新开店目标 1200-1400 家。预计 2Q24 收入增-5%-0% 由 23 年新开门店驱动,归母净利润 1.9-2.0 亿元。 (3)餐饮:4、5 月餐饮收入分别为 3915 亿元、4274 亿元,分别同比增长 4.4%、 5.0%。考虑到 2Q23 高基数及 2Q24 需求端恢复不足、客单价仍在下行,我们判断板 块收入端小幅增长(主要由开店驱动),而同店压力仍在,利润端增速相对承压。 ①百胜中国:预计 2Q24 收入增-5-5%,归母净利润增-10-0%;②海底捞:预计 1H24 收入增 0-10%,归母净利润增-5-5%;③九毛九:预计 1H24 收入增 0-10%, ...